Asthma & COPD Market Report 2016-2026

LONDON, October 27, 2016 /PRNewswire/ --

Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs

Visiongain's comprehensive new 313 page report reveals that the global asthma & COPD market will achieve revenues of $33.2bn in 2016.

Are you involved in the asthma & COPD market or intend to be? If so, then you must read this report.
It's vital that you keep your knowledge up to date. You need this report.

Market scope: Asthma & COPD are among the most common and debilitating respiratory conditions. Drugs for the treatment of these conditions fall into 3 main categories: Bronchodilator monotherapy, anti-inflammatory drugs and combination drugs. Visiongain assesses how these three submarkets and the 12 largest national markets will evolve over the forecast period.The competitive landscape is further illustrated with examination of the 7 market leading manufacturers.

The asthma & COPD Market 2016-2026 report responds to your need for definitive market data: 

• Where are the asthma & COPD market opportunities?
- 248 tables, charts, and graphs reveal market data allowing you to target your strategy more effectively

• When will the asthma & COPD market grow?
- Global, regional and asthma & COPD submarket forecasts and analysis from 2016-2026 illustrate the market progression

• Which asthma & COPD submarkets will flourish from 2016-2026?
- Individual application forecasts and analysis demonstrate the prospects
• Combination drugs forecast 2016-2026
• Anti-inflammatory drugs forecast 2016-2026
- Corticosteroids forecast 2016-2026
- Anti-Leukotrienes forecast 2016-2026
- Monoclonal antibodies forecast 2016-2026
- Other anti-inflammatories forecast 2016-2026
• Bronchodilator monotherapy forecast 2016-2026
- Short-acting beta2-agonist (SABAs) forecast 2016-2026
- Long-acting beta2-agonist (LABAs) forecast 2016-2026
- Anticholinergics forecast 2016-2026

To see a report overview please email Sara Peerun on [email protected]

• Where are the regional asthma & COPD market opportunities from 2016-2026?
- Focused regional forecasts and analysis explore the future opportunities
- US forecast 2016-2026,
- China forecast 2016-2026
- Japan forecast 2016-2026
- India forecast 2016-2026
- Germany forecast 2016-2026
- UK forecast 2016-2026
- France forecast 2016-2026
- Mexico forecast 2016-2026
- Brazil forecast 2016-2026
- Russia forecast 2016-2026

• What are the factors influencing asthma & COPD market dynamics?
- SWOT / Porter's Five Forces analysis explores the factors.
- Research and development (R&D) strategy
- Technological issues and constraints.
- Supply and demand dynamics
- Competition from new product types
- Increasing specialisation by leading players
- Advances in product quality

• Who are the leading asthma & COPD companies?
- Examine competitive positioning, product portfolios, R&D activity, M&A activity, and future outlook.
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Merck & Co. Inc (Merck)
- Novartis
- Roche
- Teva

• Who should read this report?
- Anyone within the asthma & COPD value chain, including
- CEO's
- COO's
- CIO's
- Business development managers
- Marketing managers
- Suppliers
- Technologists
- Investors
- Banks
- Government agencies
- Contractors

Get our report today Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs. Avoid missing out - order our report now.

To see a report overview please email Sara Peerun on [email protected]

To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1746/Asthma-COPD-Market-Report-2016-2026

Companies Mentioned in the Report 

3M Drug Delivery Systems

AB Science

Actavis

Alcon

Alembic

Allen and Hanburys

Allergan

Almirall

Apotex

Ario Pharma

Array BioPharma

Aspen Pharmacare

Astellas Pharma

AstraZeneca

Aurobindo Pharma

Bellephron

Ben Vue Laboratories

BioWa

BioXpress Therapeutics

Boehringer Ingelheim

Breath Limited

Bristol-Meyer Squibbs

Catalent Pharma Solutions

Cephalon

Ception Therapeutics

Chiesi Pharmaceuticals

Ciba-Geigy

Cipla

Circassia Pharmaceuticals

CVS Caremark

Daewoong Pharmaceutical

Dainippon Sumimoto

Dr. Reddy's Laboratories

Express Scripts

Forest Pharmaceuticals

Fountain Biopharma

Genentech (Roche)

Grifols

GSK

Hikma Pharmaceuticals

Ikaria

Invion

Kamada

Kyorin Pharmaceuticals

Kyowa Hakko Kirin

Lilly

Mariposa

MedicNova

Medimmune

Menarini

Merck & Co.

Mylan

Novartis

Nycomed

Omega Pharma

Orion Pharmaceuticals

Pearl Therapeutics

Perrigo

Pfizer

Prosonix

Reckitt Becnkiser

Regeneron

Roche

Roxane Laboratories

Sandoz (Novaris)

Sanofi

Schering-Plough's

SkyePharma

Sofotec

Stempeutics

Sunovion Pharmaceuticals

Synairgen

Takeda Pharmaceuticals

Tanox

Teva

Theravance

Vectura

Viatris

Watson (Actavis)

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd